Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety-Reference-Cited by-同舟云学术

Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety

Published:2020-11-22 Issue:2 Volume:128 Page:204-212
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin. Pharmacol. Toxicol.

Author:

Breining Peter¹,Frølund Anne Lier²,Højen Jesper Falkesgaard³⁴,Gunst Jesper Damsgaard³⁴^ORCID,Staerke Nina B.³⁴,Saedder Eva¹⁵,Cases‐Thomas Manuel⁶,Little Paul⁷,Nielsen Lars Peter¹⁵,Søgaard Ole S.³⁴,Kjolby Mads¹⁵⁸⁹^ORCID

Affiliation:

1. Department of Biomedicine Aarhus University Aarhus Denmark

2. Medical School Faculty of health Aarhus University Aarhus Denmark

3. Department of Clinical Medicine Aarhus University Aarhus Denmark

4. Department of Infectious Diseases Aarhus University Hospital Aarhus Denmark

5. Department of Clinical Pharmacology Aarhus University Hospital Aarhus Denmark

6. Senechæm Ltd. Reading UK

7. Lundbeck Foundation Copenhagen Denmark

8. Steno Diabetes Center Aarhus Aarhus University Hospital Aarhus Denmark

9. University of Dundee Dundee Scotland

Funder

Lundbeckfonden

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcpt.13533

Reference71 articles.

1. Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options;Khan S;Journal of Clinical Microbiology,2020

2. What we know so far: COVID-19 current clinical knowledge and research

3. SARS-CoV-2 was already spreading in France in late December 2019

4. WHO.Virtual press conference on COVID‐19 – 11 March 2020. Secondary Virtual press conference on COVID‐19 – 11 March 2020 11 March 2020.https://www.who.int/docs/default‐source/coronaviruse/transcripts/who‐audio‐emergencies‐coronavirus‐press‐conference‐full‐and‐final‐11mar2020.pdf?sfvrsn=cb432bb3_2

5. COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel compounds with dual inhibition activity against SARS-CoV-2 critical enzymes RdRp and human TMPRSS2;European Journal of Medicinal Chemistry;2024-10

2. Safety and Efficacy of Camostat Mesylate for Covid-19: a systematic review and Meta-analysis of Randomized controlled trials;BMC Infectious Diseases;2024-07-19

3. Influenza, SARS-CoV-2, and Their Impact on Chronic Lung Diseases and Fibrosis;The American Journal of Pathology;2024-07

4. Need and Possibilities of Phytocompounds against SARS-CoV-2: Recent Advances in COVID-19 Therapy;Current Traditional Medicine;2024-02

5. Antiandrogens as Therapies for COVID-19: A Systematic Review;Cancers;2024-01-10